The interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin was studied by equilibrium dialysis. A 20-fold variation of buffer ionic strength (0.017-0.340) caused no significant change in the warfarin association constant. But the binding strength rose significantly as the pH was increased from 6.0 to 9.0 and then declined at pH 10.0. The 6-, 7-, and 8-hydroxywarfarin metabolites showed a 7-to 23-fold reduction in binding strength at pH 10.0. These data indicate that the molecular basis of the interaction is nonelectrostatic and that the introduction of polar hydroxyl groups on the coumarin nucleus by metabolism reduces its hydrophobic binding surface. The interaction was markedly exothermic and showed a positive entropy (increased molecular disorder), which suggests cooperative hydrogen and hydrophobic bonding as the molecular basis for the binding of warfarin to albumin.
A B S T R A C T The interaction of the anticoagulant drug warfarin and its metabolites with human plasma albumin was studied by equilibrium dialysis. A 20-fold variation of buffer ionic strength (0.017-0.340) caused no significant change in the warfarin association constant. But the binding strength rose significantly as the pH was increased from 6.0 to 9.0 and then declined at pH 10.0. The 6-, 7-, and 8-hydroxywarfarin metabolites showed a 7-to 23-fold reduction in binding strength at pH 10.0. These data indicate that the molecular basis of the interaction is nonelectrostatic and that the introduction of polar hydroxyl groups on the coumarin nucleus by metabolism reduces its hydrophobic binding surface. The interaction was markedly exothermic and showed a positive entropy (increased molecular disorder), which suggests cooperative hydrogen and hydrophobic bonding as the molecular basis for the binding of warfarin to albumin.
The marked albumin binding and nonpolar character of warfarin explains the respective absence and presence of the unchanged drug in urine and plasma of warfarintreated patients, while the more polar character and lesser albumin binding of the metabolites probably determines their absence in plasma and presence in urine. The relatively marked binding to albumin of the 4'-hydroxywarfarin metabolite suggests that it may occur in the plasma of warfarin-treated patients. The data suggest that a direct correlation exists between the interaction of warfarin with plasma albumin and the interaction with the warfarin receptor site.
INTRODUCTION
In previous studies of the interaction of the coumarin anticoagulant warfarin sodium and human plasma albumin, the drug was strongly bound to plasma albumin when analyzed by equilibrium dialysis (1) . While the strength of the interaction was studied as a function of temperature, no experiments were performed at different levels of buffer pH and ionic strength. Such experiments were performed in the present study which together with the thermodynamic data allowed us to analyze the molecular basis of the warfarin-albumin interaction.
Countercurrent distribution analysis of plasma of patients receiving clinical doses of warfarin shows essentially only the unchanged drug and similar analysis of urine reveals only hydroxylated metabolites of warfarin (2, 3) . To determine if the absence of the metabolites in plasma and the absence of unchanged drug in the urine could be correlated with albumin binding, we also studied the four known metabolites by equilibrium dialysis. Based on these data, a hypothesis is presented for the pharmacodynamics of warfarin in man.
METHODS

Warfarin sodium
Material. The equilibrium dialysis technique, the crystalline human albumin and warfarin sodium, the preparation of the cellophane bags, the experimental techniques employed, the measurement of free and bound drug, and the determination of the standard free energy change were exactly as described previously (1) . The low concentrations of warfarin sodium were varied over a 16-fold range (6-100 ,moles/ liter), which evaluates mainly the association constant of the first warfarin anion bound (k1). The concentration of The Journal of Clinical Investigation Volume 48 1969 193 albumin used in all experiments was 0.4% (57.9 /hM/liter). The experiments on the effect of the ionic strength of the medium were carried out over a 20-fold range of phosphate buffer, 0.0067-0.134 M (ionic strength 0.0174.340), at pH 7.4 and 270C. The experiments on the effect of the pH of the medium were carried out in sodium and potassium phosphate buffer for pH 6.0 and 7.4, in potassium phosphatesodium borate buffer for pH 9.0, and in sodium boratesodium carbonate buffer for pH 10.0, all at 0.170 ionic strength (j) and 270C. The molar extinction coefficient of warfarin showed no significant variation on raising the pH from 6 to 10. Experiments could not be be performed at a pH of < 6 because of marked precipitation of the drug.
Methods. Human plasma albumin,' prepared by repeated crystallization from Cohn fraction V, was used in all experiments. By cellulose acetate electrophoretic analysis, the albumin was 100% pure. The water content of the albumin, evaluated by heating a small sample in an oven at 1100 C until a constant weight was obtained, was found repeatedly to be less than 17%; therefore, no correction for water content was required. The 0.4% albumin solution was prepared in phosphate buffer, 0.067 mole/liter, pH 7.4, unless otherwise specified. Two forms of warfarin, (3-(a-acetonylbenzyl)-4-hydroxy-coumarin) were used: a clathrate prepared by repeated crystallization of amorphous warfarin sodium from isopropyl alcohol (91.2% warfarin sodium), and an amorphous powder prepared by commercial methods (91.0% warfarin sodium, with 3.15%o loss on drying to a constant weight (1).2 When corrected for the difference in warfarin sodium content, the results obtained with the two forms of the drug did not vary significantly.
Dialysis bags were made from if inch cellophane casing (Union Carbide Corp., Visking Div., Chicago, Ill.). The casings were cleaned by continuous rinsing in a recycling bath of deionized water for 8 hr and could then be stored up to 10 days in deionized water at 4VC. Just before use the bags were washed repeatedly with deionized water, followed by the phosphate buffer; they were not allowed to dry. With this technique the optical density of blank buffer carried through a run at the maximal wavelength of warfarin was always less than 0.005.
Experimental. 10 ml of albumin-buffer solution was added inside the dialysis bag, and 15 ml of warfarin solution was added outside. To warfarin (1) . The concentration of free warfarin anion in equilibrium with bound anion was determined by measuring the drug concentration outside the dialysis bag. The method used for determining warfarin content (3) will detect concentrations as low as 5 Amoles/liter and has an error of 2%. The amount of albumin-bound warfarin was determined by subtracting the free and bag-bound warfarin from the amount added initially. The accuracy of the method was verified in separate experiments with warfarin-'4C (4.35 jc/mg) ,3 in which the labeled warfarin inside and outside the dialysis bags was determined by liquid scintillation counting. The results obtained by the two methods at all concentrations of warfarin varied less than 1%. Whether the drug was added initially to the inside or outside of the dialysis bag had no effect on the percentage of warfarin bound to albumin.
Metabolites
Material. The urinary metabolites of warfarin sodium in man and rat have been identified and synthesized (4, 3) . These were obtained as a white crystalline powder and diluted in buffer without any further purification.s All four metabolites at the concentrations studied (6-100 Amoles/ liter) were insoluble at pH 7.4, but were readily soluble at pH 10.0. The competitive equilibrium dialysis experiments with 7-hydroxywarfarin, nonradioactive warfarin sodium, and warfarin-'4C were performed as described previously (5) .
Methods. The conditions of the competitive equilibrium dialysis experiments were as follows: the pH was adjusted to 10 .0 with the use of 0.15 M sodium borate in sodium carbonate buffer; the dialysis bags contained human albumin in a concentration of 0.4% (57.9 ,uM/liter) and '4C-labeled warfarin sodium in concentrations varying from 2 (6.06 AM/ liter) to 32 mg/liter (96.7 AIM/liter). At equilibrium, aliquots of the solutions inside and outside the bag were analyzed for radioactivity in a Tri-Carb liquid scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.). Similar experiments were carried out with labeled warfarin sodium and albumin solutions inside the bags and either nonradioactive warfarin or nonradioactive 7-hydroxywarfarin, 32 mg/liter (96.7 AM/liter), in the dialysis tube outside the bag. At equilibrium for the labeled warfarin sodium, aliquots were collected and counted for radioactivity as before to determine the concentration of bound warfarin in the presence of either "cold" warfarin or "cold" 7-hydroxywarfarin. The diminution in the binding of warfarin sodium was used to calculate the association constants to albumin by means of the following equation of Edsall and Wyman (6):
in which kA is the association constant for labeled warfarin sodium alone, hA' is the warfarin sodium association constant in the presence of the "cold" compound, (B) is the molar concentration of the "cold" compound, and kB is the apparent association constant of the nonradioactive (cold) compound for albumin.
The equilibrium dialysis experiments with the four metabo-3 Hermodson, M., and K. P. Link. 1967. Personal communication.
lites were carried out under exactly the same conditions as for warfarin sodium. The concentration of each metabolite was determined spectrophotometrically by measuring the optical density at its ultraviolet absorption maximum. 
Calculations
The binding constants for the interaction were analyzed as before (1) by means of the Scatchard equation for the law of mass action (7) v/A = kn -kv5, where v is the molar ratio of bound warfarin to albumin, A is the molar concentration of free warfarin at equilibrium, k is the average association for the binding at each site, and n is the average maximum number of binding sites on the albumin molecule. For each compound studied v, and v/A and their standard errors at every concentration used were calculated.5 A regression line was calculated for each set of data by the method of least squares, and kn (equal to the first anion bound or k1) and n were determined by extrapolation as in the previous study (1) . The values of v/A plotted against v give a straight line when all the binding sites are independent and equivalent. Deviations from linearity can arise from interaction of the bound anions or from the occurrence of binding at more than one class of sites with different association constants. As vF/A approaches zero as a limit, the intercept on the v axis (abscissa) is n, and as v approaches zero as a limit, the intercept on the v/A axis (ordinate) is kn the classical association constant for the first anion bound. The standard free energy change of binding for the first anion bound (AF,') was determined from k, by the general thermodynamic relationship AF1°=-RT ln ki, where R is the gas law constant and T is the absolute temperature.
RESULTS
The effects of varying the buffer ionic strength on the interaction of warfarin and human plasma albumin at pH 10.0 and 270C are reported in Tables I and II. Raising the ionic strength from 0.017 to 0.340 resulted both inside and outside the bags, rather than on a correct basis of a 10 ml volume for the albumin solution, the volume inside the bags. Hence v and therefore v/A were too low by a factor of 25/10 or 2.5. We are grateful to Doctors D. E. Guttman and M. C. Meyer of the State University of New York at Buffalo School of Pharmacy for bringing this fact to our attention. kl, average association constant for the first warfarin anion bound; AF10, standard free energy change for the first warfarin anion bound.
in less than 2% variation in log ki and AF1°. The number of binding sites remained essentially unchanged and averaged 1.9 for all the compounds. The results of varying the pH of the buffer (270C and ionic strength 0.170) are reported in Table III ; the results at pH 7.4 are seen in Table I Figure 2 . The 6-, 7-, and and 8-hydroxywarfarin, in which the hydroxyl group is inserted on the benzpyran part of the coumarin nucleus, showed markedly less binding than unchanged warfarin, with ki 7-23 times less for these metabolites (Table II) . But ki for 4'-hydroxywarfarin, in which the hydroxyl group is present on the benzyl group of the side chain, was only E1fold less bound than the unchanged drug. The AFi0 2 was 1.2-1.9 kcal/mole less for the 6-, 7-, and 8-hydroxywarfarin than for unchanged warfarin. The AFi0 was only 0.3 kcal/mole less than the unchanged drug for the 4'-metabolite. fect ligand-protein bonds (9) . The possible sources of error in the dialysis experiments were membrane adsorption of drug, a Donnan effect, denaturation of the protein and pH changes during dialysis, and alteration in the membrane pore size. There was no evidence of any of these physicochemical changes probably because equilibrium of the drug and its metabolites was achieved at all concentrations within 4 hr. The membrane adsorption of unchanged warfarin in these experiments was about 1% of the free drug concentration, which is significantly lower than that observed previously (1 (11) . Changes in ionic strength can also alter the dielectric constant of the medium and hence the binding interaction, but with the moderately dilute solutions used in these studies the dielectric constant probably did not vary significantly. A lack of change of binding affinity during variation in ionic strength ruled out any significant ionic interaction between warfarin and albumin. This is not surprising as warfarin is a weakly acidic anion (pKa 5.1) and has no strongly ionizing groups. Most previous studies on anion-albumin binding that have shown marked electrostatic interactions (12) were performed with compounds (organic dyes and sulfa drugs) with strong ionizing groups (sulfates).
DISCUSSION
The data clearly indicate that on raising the pH from 6.0 to 9.0 the strength of the warfarin-albumin interaction surprisingly increased. With a rising pH and hence an increasing negative charge on the protein, a substantial decrease in the ability to attract anions might be anticipated (13) . At a pH of 6, the basic amino acids ar- ginine, histidine, and lysine combine with a hydrogen ion and hence have a net positive charge, whereas the acidic amino acids, such as glutamic acid, release a hydrogen ion and form carboxylate ions (14) . Since the isoelectric point of plasma albumin is near pH 5, the number of carboxylate ions at pH 6 exceeds the number of quarternary nitrogen atoms and thus the net charge on the protein is negative. Nevertheless, the presence of the positively charged nitrogen atoms apparently forms a focus of attachment for the anionic warfarin. Thus, one would expect the binding to decrease at a pH where the quarternary nitrogen atoms lose their hydrogen ions. The region of decreased binding of warfarin and albumin (above pH 9) corresponds to the region in which the e-amino group of lysine loses its hydrogen ion (pH 9.-10.6) (14) . While the increase in warfarin-albumin interaction with the increase in pH from 7.4 to 9.0 is consistent with the uncovering of new binding sites on the albumin molecule, it is inconsistent with an electrostatic mechanism: an increasing number of negative charges on the protein should lead to a decrease in binding (14) .
Changes in the availability of tyrosine hydroxyl groups and in the configuration of the protein molecule occur in human plasma albumin at pH levels above 7, arising apparently from a reversible swelling or unfolding of the molecule (13) . It seems likely that the change in configuration of albumin with rising pH is not the result of dissociation of any specific side chain or of any change in the helical content (15) but rather an effect of a swelling or unfolding induced by the strong electrostatic repulsions that develop in the protein molecule as its negative charge increases beyond -10 at pH 7.6 and higher (16) . In our previous study of the warfarinalbumin interaction (1), the very act of complex formation with anions apparently increases the net negative charge of the albumin and makes more sites available for further binding (16) . This mechanism could account for the continued failure of all attempts to find an actual plateau on graphs for the number of ions of warfarin bound, or any other anion noncovalently bound to albumin, plotted against the free ion concentration (1). The increase in binding strength of an anion to albumin when the pH is raised above 7.4 also occurs with bilirubin (17), L-tryptophan (18) , testosterone (19) , thyroxine (20) , penicillin (21) , organic dyes (13), and sulfa drugs (12) .
The metabolites bound to human plasma could not be subjected to continuous flow electrophoresis to prove their exclusive binding to the albumin fraction. However, this has been demonstrated for unchanged warfarin, and no instance has been reported of a drug bound to albumin whose metabolites were bound significantly to a nonalbumin fraction (1) . Additionally, the competition of unchanged warfarin and one of its metabolites for albumin could be evaluated by competitive equilibrium dialysis, as the relative ability of analogues to displace a compound from albumin can be taken as a measure of the relative affinity of the analogues for albumin (6) .
The close agreement of the association constant for 7-hydroxywarfarin determined by direct dialysis and by competitive dialysis indicates the absence of any significant nonalbumin binding for this warfarin metabolite (8) .
The 6-, 7-, and 8-hydroxywarfarin metabolites were bound to albumin 7-to 23-fold less than the unchanged drug. Unlike unchanged warfarin, the metabolites appeared to have only a single class of binding sites that were of the same order of binding magnitude as the lower class of sites of the unchanged drug. However, the limited availability of the metabolites prevented study of them at higher concentrations. The 4'-hydroxywarfarin metabolite showed only a slight decrease in binding strength from that of unchanged warfarin. As shown in Fig. 3 , the 6, 7, and 8 positions of the warfarin molecule occur on the benzpyran portion of the coumarin nucleus, while the 4' position is located on the benzyl group of the side chain. The binding energy of the coumarin nucleus metabolites (Table II) 10 and 27°C. This indicates that under physiologic conditions of pH 7.4 and 37°C the benzpyran portion of the warfarin molecule contributes at least 2.0 kcal/mole of the 7.5 kcal/mole of its binding energy to albumin. Similarly, in studies of corticosteroids increasing the number of polar substituents by hydroxylation and hydrogenation depressed the binding to plasma albumin (22) .
The binding of warfarin to human plasma albumin (complex formation) at pH 7.4 and 37°C results in a free energy change of about -7.6 kcal/mole. About 40% of the source of this free energy change (-3 kcal/mole) is the result of the favorable enthalpy of the reaction (1), which has been confirmed by direct calorimetric measurement.' The remaining part of the free energy change is derived from a favorable entropy change (+ 15 electrostatic units). Simplistically, one would expect the entropy change on complex formation to be markedly negative because of a restriction of translational and rotational entropy accompanying the decrease in the number of ions in solution (23) . It is unlikely that the positive entropy change is the result of significant disorientation of the albumin molecule, at least for the first warfarin anion bound, as the reaction is exothermic whereas a process of unfolding with the breaking of bonds would be an endothermic reaction (24) . However, the role of the aqueous solvent must be considered. When a compound is dissolved in a polar solvent, the solvation of ions and polar groups is a large factor in reducing the entropy of the system (25) . Because the albumin and warfarin molecules are hydrated on solution in aqueous solvent, there should be an increase in the number of molecular species on binding because of the release of water of solvation from both the warfarin and albumin molecules; hence, one would expect an increase in entropy for the interaction (25 The interaction of drugs with proteins represents an important aspect of drug metabolism because of the interactions with a) receptor proteins which may result in pharmacologic activity of the drug, b) an enzyme responsible for the degradation of the drug, and c) inert proteins of blood (albumin) or tissue which may be responsible for the distribution and transport of the drug and may limit its activity or metabolism (31) . All three of these aspects of drug metabolism have been studied with warfarin in man: the first by the prothrombinopenic response (2) , the second by the half-life of the drug in plasma and its correlation with the duration of the anticoagulant effect (32) , and the third by the warfarin-albumin interaction described herein. Administration of the 6-, 7-, and 8-hydroxywarfarin metabolites to rats does not produce an anticoagulant effect (4). penic effect in man and rat. These findings suggest that a direct correlation exists between the interaction of warfarin with plasma albumin and with its receptor site. Thus, the high degree of albumin binding and nonpolar character of warfarin would account for its high levels in plasma, low levels in urine, and small volume of distribution (2) , and the low protein binding and more polar character of the warfarin metabolites would account for their low levels in plasma and high levels in urine (3) . However, these findings should not be extrapolated as generalizations for human metabolism. The clearance of some sulfate ester metabolites of pregnenolone and its derivatives is actually slower than that of the unchanged compound, the volume of distribution is smaller, and the half-lives in plasma are longer (34) . The lack of increased sensitivity of response to coumarin anticoagulants in patients with uremia suggests that the metabolites are devoid of anticoagulant activity and that the unchanged drug is not cleared by the normal human kidney (35) . We reported a metabolite of warfarin with an ultraviolet absorption maximum of 320 mu in the urine of man (3) . Since the ultraviolet absorption maxima of the four known warfarin metabolites are 302, 304, 308, and 330 mu, the previous maximum of 320 mu probably represents more than one urinary metabolite of the drug.
Recently, a photofluorometric method for the determination of warfarin was described (36) . This method consistently gives higher values than the ultraviolet spectrophotometric method (3) for plasma of warfarintreated patients, but gives identical values when warfarin is added to plasma in vitro.7 The marked binding to albumin and marked fluorescence7 of the 4'-hydroxywarfarin metabolite suggest that it may occur in the plasma of warfarin-treated patients which would account for the consistently higher readings for warfarin obtained by the fluorometric method. The similar physical properties of warfarin and its metabolite 4'-hydroxywarfarin (marked albumin binding and an identical ultraviolet absorption maxima of 308 mtL) may explain the previous inability to separate the two by countercurrent distribution with spectral measurement at 308 mu and therefore to wrongly conclude that the spectrophotometric assay for unchanged warfarin in biologic specimens was specific (3) .
